- Home
- PROK vs SSSS Comparison
PROK vs SSSS Comparison
Compare PROK & SSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- SSSS
- Stock Information
- Founded
- PROK 2015
- SSSS 2010
- Country
- PROK United States
- SSSS United States
- Employees
- PROK N/A
- SSSS N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- SSSS Finance: Consumer Services
- Sector
- PROK Health Care
- SSSS Finance
- Exchange
- PROK Nasdaq
- SSSS Nasdaq
- Market Cap
- PROK 126.8M
- SSSS 137.0M
- IPO Year
- PROK N/A
- SSSS N/A
- Fundamental
- Price
- PROK $0.84
- SSSS $5.38
- Analyst Decision
- PROK Buy
- SSSS Buy
- Analyst Count
- PROK 4
- SSSS 2
- Target Price
- PROK $5.00
- SSSS $8.00
- AVG Volume (30 Days)
- PROK 434.6K
- SSSS 225.9K
- Earning Date
- PROK 05-09-2025
- SSSS 03-11-2025
- Dividend Yield
- PROK N/A
- SSSS N/A
- EPS Growth
- PROK N/A
- SSSS N/A
- EPS
- PROK N/A
- SSSS N/A
- Revenue
- PROK $76,000.00
- SSSS $4,673,427.00
- Revenue This Year
- PROK N/A
- SSSS N/A
- Revenue Next Year
- PROK N/A
- SSSS N/A
- P/E Ratio
- PROK N/A
- SSSS N/A
- Revenue Growth
- PROK N/A
- SSSS N/A
- 52 Week Low
- PROK $0.80
- SSSS $3.52
- 52 Week High
- PROK $4.44
- SSSS $6.83
- Technical
- Relative Strength Index (RSI)
- PROK 29.40
- SSSS 45.68
- Support Level
- PROK $0.87
- SSSS $5.65
- Resistance Level
- PROK $1.00
- SSSS $5.99
- Average True Range (ATR)
- PROK 0.10
- SSSS 0.29
- MACD
- PROK 0.01
- SSSS -0.06
- Stochastic Oscillator
- PROK 14.70
- SSSS 42.96
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.